Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, BMS Advance Neuroscience Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, BMS Advance Neuroscience Alliance

Bolsters joint pipeline of advanced neuroscience programs triggering a $25 million payment to further research.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec SE has progressed its strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programs, triggering a $25 million payment to further research efforts.
 
The companies entered a strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases where there remains a significant unmet medical need to slow down or reverse disease progression.
 
The partnership has generated a promising pipeline of discovery to clinical-stage programs. The first program, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. Following a successful Phase I study Bristol Myers Squibb announced that a Phase II study for BMS-986419 is scheduled to begin in 2024. In March 2023, the companies extended and expanded the partnership for an additional eight years.
 
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “As the first asset from our neuroscience partnership with Bristol Myers Squibb is moving towards a Phase II study, our partnership is still growing in the drug discovery phase as well. We are confident that our unique PanOmics-based and patient-derived cellular models supported drug discovery efforts will deliver new therapeutic options for patients affected by devastating neurological disorders.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics